LIGAND PHARMACEUTICALS INCORPORATED
Profit Margins
| Period | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| Mar 2017 | 98.8% | 34.9% | 154.7% |
| Jun 2017 | 96.8% | 46.5% | 261.3% |
| Sep 2017 | 92.9% | 49.4% | 201.8% |
| Dec 2017 | — | — | -84.2% |
| Mar 2018 | 98.6% | 66.0% | 80.6% |
| Jun 2018 | 98.7% | 77.9% | 81.3% |
| Sep 2018 | 96.8% | 51.2% | 147.5% |
| Dec 2018 | — | — | -71.3% |
| Mar 2019 | 91.1% | 1,900.8% | 1,532.4% |
| Jun 2019 | 90.4% | -16.5% | -57.7% |
| Sep 2019 | 87.3% | -20.8% | -61.5% |
| Dec 2019 | — | — | -27.3% |
| Mar 2020 | — | 11.4% | -72.8% |
| Jun 2020 | — | 17.1% | 53.3% |
| Sep 2020 | — | 9.0% | -16.0% |
| Dec 2020 | — | — | 8.2% |
| Mar 2021 | — | 10.1% | 38.9% |
| Jun 2021 | — | 58.0% | 39.0% |
| Sep 2021 | — | 26.3% | 23.0% |
| Dec 2021 | — | — | -9.6% |
| Mar 2022 | — | 5.8% | -42.1% |
| Jun 2022 | — | 17.3% | -1.8% |
| Sep 2022 | — | 20.8% | 0.7% |
| Dec 2022 | — | — | -34.7% |
| Mar 2023 | — | 32.3% | 95.4% |
| Jun 2023 | — | -7.5% | 8.7% |
| Sep 2023 | — | 9.4% | -31.3% |
| Mar 2024 | — | 9.6% | 278.1% |
| Jun 2024 | — | -46.0% | -125.0% |
| Sep 2024 | — | 6.1% | -13.8% |
| Mar 2025 | — | -79.9% | -93.6% |
| Jun 2025 | — | 17.7% | 10.2% |
| Sep 2025 | — | 47.6% | 101.6% |
| Mar 2026 | — | 33.6% | -25.8% |
| Jun 2026 | — | 13.5% | 76.2% |